Search alternatives:
significant benefits » significant effects (Expand Search)
long decrease » point decrease (Expand Search), nn decrease (Expand Search), coping decreased (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
Showing 1 - 20 results of 3,207 for search '(( significant ((long decrease) OR (fold decrease)) ) OR ( significant benefits decrease ))', query time: 0.53s Refine Results
  1. 1
    Screening for gHgLgO interaction partners reveals decreased binding of the gO249 mutant to cell surfaces.

    Screening for gHgLgO interaction partners reveals decreased binding of the gO249 mutant to cell surfaces. by Lena Thiessen (17605194)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 <sup>a</sup> indicates ≥1.50 SD (17.9) from the mean (32.9), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 <sup>a</sup> indicates ≥1.50 SD (17.9) from the mean (32.9... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.4), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 <sup>a</sup> indicates ≥1.50 SD (16.0) from the mean (29.9), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 <sup>a</sup> indicates ≥1.50 SD (16.0) from the mean (29.9... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 <sup>a</sup> indicates ≥1.50 SD (19.2) from the mean (34.8), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 <sup>a</sup> indicates ≥1.50 SD (19.2) from the mean (34.... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Summary of Biomarker Expression in Benign Samples. The STT and LTT groups exhibit significant changes in biomarker expression compared to the nontreatment group, measured on a two-fold logarithmic scale. STT: Short-term dihydrotestosterone treatment. LTT: Long-term dihydrotestosterone treatment.

    Summary of Biomarker Expression in Benign Samples. The STT and LTT groups exhibit significant changes in biomarker expression compared to the nontreatment group, measured on a two-... by Jinho Lee (587173)

    Published 2025
    Save to List
    Saved in:
  9. 9
    (A) Rapid light curves, (B) maximum electron transport rates (ETR<sub>max</sub>) and (C) minimum saturating irradiances (E<sub>k</sub>) derived from the model fitted according to Platt et al.

    (A) Rapid light curves, (B) maximum electron transport rates (ETR<sub>max</sub>) and (C) minimum saturating irradiances (E<sub>k</sub>) derived from the model fitted according to P... by Malte Ostendarp (13217973)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    (A) Rapid light curves, (B) maximum electron transport rates (ETR<sub>max</sub>) and (C) minimum saturating irradiances (E<sub>k</sub>) derived from the model fitted according to Platt et al.

    (A) Rapid light curves, (B) maximum electron transport rates (ETR<sub>max</sub>) and (C) minimum saturating irradiances (E<sub>k</sub>) derived from the model fitted according to P... by Malte Ostendarp (13217973)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Symbiodiniaceae cell density of (A) <i>Acropora</i> sp. and (B) <i>P. verrucosa</i>, areal chlorophyll content of (C) <i>Acropora</i> sp. and (D) <i>P. verrucosa</i>, and chlorophyll content per cell of (E) <i>Acropora</i> sp. and (F) <i>P. verrucosa</i> for the four groups.

    Symbiodiniaceae cell density of (A) <i>Acropora</i> sp. and (B) <i>P. verrucosa</i>, areal chlorophyll content of (C) <i>Acropora</i> sp. and (D) <i>P. verrucosa</i>, and chlorophy... by Malte Ostendarp (13217973)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Hypothesized effect of (A) heat stress and (B) heat stress in combination with molecular hydrogen on the coral holobiont ecophysiology.

    Hypothesized effect of (A) heat stress and (B) heat stress in combination with molecular hydrogen on the coral holobiont ecophysiology. by Malte Ostendarp (13217973)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Photosynthesis and respiration rates of (A) <i>Acropora</i> sp. and (B) <i>P. verrucosa</i> for the four groups.

    Photosynthesis and respiration rates of (A) <i>Acropora</i> sp. and (B) <i>P. verrucosa</i> for the four groups. by Malte Ostendarp (13217973)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Supplementary data.

    Supplementary data. by Malte Ostendarp (13217973)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Photosynthetic efficiency (<i>Fv/Fm</i>) of (A) <i>Acropora</i> sp. and (B) <i>P. verrucosa</i> for the four groups.

    Photosynthetic efficiency (<i>Fv/Fm</i>) of (A) <i>Acropora</i> sp. and (B) <i>P. verrucosa</i> for the four groups. by Malte Ostendarp (13217973)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Kaplan-Meier curves and time-dependent Cox regression for outcome of mortality.

    Kaplan-Meier curves and time-dependent Cox regression for outcome of mortality. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 17
    Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE.

    Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 18
    Adverse cardiovascular events by immune checkpoint inhibitor.

    Adverse cardiovascular events by immune checkpoint inhibitor. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 19
    Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events.

    Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 20
    Minimal dataset.

    Minimal dataset. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: